Introduction: Myeloid malignancies are a heterogeneous group of clonal bone marrow disorders that are complex to manage in the community and therefore often referred to subspecialists at tertiary oncology referral centers. Many patients do not live in close proximity to tertiary referral centers and are unable to commute long distances due to age, comorbidities, and frailty. Interventions that minimize the travel time burden without compromising quality of care are an area of unmet need. We describe a cancer care delivery model for patients with myeloid malignancies that is built around telehealth and enables this vulnerable population access to care at an NCI-designated cancer center while receiving majority of their care close to home. Methods and Materials: We report on a cohort of patients with myeloid malignancies who were co-managed by a general community oncologist and an academic leukemia subspecialist at Montefiore Einstein Cancer Center in New York. Patients were initially referred to our institute for a second opinion by community practices that are in partnership with Montefiore Health System, and initial visits were in-person or via telehealth. Treatment plans were made after discussion with patient’s local community oncologist. Patients then continued to receive majority of their treatment and supportive care including transfusion support with their local oncologist, and follow-up visits were mainly via telehealth with the academic leukemia subspecialist. Results: Our cohort of 12 patients had a median age of 81 years (range, 59–88 years). Patients remained on active treatment for a median time of 357 days (range, 154–557 days). Most of our patients had a performance status of ECOG 2 or higher. Three patients had myelodysplastic syndromes, 7 patients had acute myeloid leukemia, and 2 patients had myelofibrosis. The median number of hospitalizations over the total treatment time period was one. Conclusion: We demonstrate a shared academic and community care co-management model for the treatment of myeloid malignancies in elderly, frail patients using telehealth as a backbone with a very low hospitalization rate.

Keywords:
Myelodysplastic syndromes, Acute myeloid leukemia, Healthcare delivery, Co-management model
1.
Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358–74.
2.
Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, et al. Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. Cancer. 2018;124(9):1938–45.
3.
Bhatt VR, Shostrom V, Giri S, Gundabolu K, Monirul Islam KM, Appelbaum FR, et al. Early mortality and overall survival of acute myeloid leukemia based on facility type. Am J Hematol. 2017;92(8):764–71.
4.
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–29.
5.
Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(11):1399–420.
6.
Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.
7.
Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019;33(12):2795–804.
8.
Royce TJ, Sanoff HK, Rewari A. Telemedicine for cancer care in the time of COVID-19. JAMA Oncol. 2020;6(11):1698–9.
9.
Ambroggi M, Biasini C, Del Giovane C, Fornari F, Cavanna L. Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist. 2015;20(12):1378–85.
10.
Jensen CE, Heiling HM, Beke KE, Deal AM, Bryant AL, Coombs LA, et al. Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens. Haematologica. 2022.
11.
Ueda M, Gupta D, Caimi PF, Creger R, Little J, William BM. Hospitalization rates in elderly, newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients treated with azacitidine. J Clin Oncol. 2015;33(15_Suppll):e18040.
12.
El-Jawahri AR, Traeger LN, Kuzmuk K, Eusebio JR, Vandusen HB, Shin JA, et al. Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. Cancer. 2015;121(6):951–9.
13.
Jillella AP, Arellano ML, Gaddh M, Langston AA, Heffner LT, Winton EF, et al. Comanagement strategy between academic institutions and community practices to reduce induction mortality in acute promyelocytic leukemia. JCO Oncol Pract. 2021;17(4):e497–505.
14.
West H, Tan YA, Barzi A, Wong D, Parsley R, Sachs T. Novel program offering remote, asynchronous subspecialist input in thoracic oncology: early experience and insights gained during the COVID-19 pandemic. JCO Oncol Pract. 2022;18(4):e537–50.
15.
US Food and Drug Administration. Oncology (cancer)/hematologic malignancies approval notifications. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications (accessed 8 March, 2022).
© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.